Tenaya Therapeutics Inc Stock

$0.52

8.11% yesterday

Nasdaq, Apr 03, 10:17 pm CET

ISIN

US87990A1060

Symbol

TNYA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Tenaya Therapeutics Inc Stock price

$0.52

-14.83 96.61% 5Y

Nasdaq, Closing price Thu, Apr 03 2025

-0.05 8.11%

ISIN

US87990A1060

Symbol

TNYA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$84.54m
Enterprise Value	$36.70m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	0.48
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-115.95m
Free Cash Flow (TTM) Free Cash Flow	$-91.53m
Cash position	$61.45m
EPS (TTM) EPS	$-1.31
P/E forward	negative
P/S forward	39.45
EV/Sales forward	17.13
Short interest	8.09%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Tenaya Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Tenaya Therapeutics Inc forecast:

9x Buy

100%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Tenaya Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Tenaya Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	8.47 8.47	28% 28% -
Gross Profit	-8.47 -8.47	28% 28% -
- Selling and Administrative Expenses	12 12	29% 29% -
- Research and Development Expense	87 87	12% 12% -
EBITDA	-107 -107	10% 10% -
- Depreciation and Amortization	8.47 8.47	28% 28% -
EBIT (Operating Income) EBIT	-116 -116	12% 12% -
Net Profit	-111 -111	10% 10% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Tenaya Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

4 days ago

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I Two of Three Patients Experienced Improvements in One or More Measures of Hypertrophy Expects to Complete Enrollment of Cohort 2 in 1H25 and to Report ...

Neutral

GlobeNewsWire

●

11 days ago

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publications of positive preclinical data for TN-201, the company's gene therapy candidate for Myosi...

Neutral

GlobeNewsWire

●

16 days ago

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201

More Tenaya Therapeutics Inc News

Company Profile

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. It operates through its product platforms: gene therapy, cellular regeneration, and precision medicine. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Olson in 2016 and is headquartered in South San Francisco, CA.

Head office	United States
CEO	Faraz Ali
Employees	97
Founded	2016
Website	www.tenayatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now